Haffajee, Rebecca L. <br/><br/>
Marijuana Rescheduling — A Game Changer for Research? 

 - páginas: 729-731 
<br/><br/> On April 22, 2026, the U.S. acting attorney general issued a final rule immediately reclassifying state-licensed medical marijuana products and future Food and Drug Administration (FDA)–approved marijuana products under Schedule III of the Controlled Substances Act. Medical marijuana (cannabis containing ≥0.3% tetrahydrocannabinol), now legal in 40 states, three territories, and the District of Columbia, was previously federally designated as a Schedule I drug — the category of drugs that are the most tightly controlled. 
<br/><br/><label>Subjects--Topical Terms: </label><br/> MEDICAMENTOS, DISPOSITIVOS Y LA FDA<br/>HEMATOLOGÍA<br/>ONCOLOGÍA GENERAL<br/>DOLOR<br/>TRATAMIENTOS EN ONCOLOGÍA<br/>DERECHO SANITARIO